Bluejay Diagnostics (NASDAQ:BJDX) Stock Price Down 6.2% – Time to Sell?

Bluejay Diagnostics, Inc. (NASDAQ:BJDX)’s stock price was down 6.2% on Friday . The company traded as low as $1.29 and last traded at $1.36. Approximately 316,918 shares traded hands during mid-day trading, an increase of 455% from the average daily volume of 57,085 shares. The stock had previously closed at $1.45.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Wall Street Zen upgraded Bluejay Diagnostics to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Monday, November 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Bluejay Diagnostics Stock Down 6.2%

The firm has a market capitalization of $2.46 million, a PE ratio of -0.01 and a beta of 0.60. The business has a 50-day moving average price of $1.92 and a 200-day moving average price of $1.71.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Friday, November 7th. The company reported ($1.01) earnings per share (EPS) for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.